Estracell Wedge Edge sponge now available at retailers nationwide
WALLED LAKE, Mich. Armaly Brands has expanded the distribution of its Estracell Wedge Edge sponge.
The Wedge Edge sponge, a multi-surface, no scratch scrub sponge that features a patent-pending, 30-degree angle shape that reaches deeper into hard-to-get-to corners and crevices, now will be available at such retailers as Walmart, Winn-Dixie, Spartan Stores, Publix.
“Consumer demand has driven retailers to make the Wedge Edge available in outlets nationwide,” said John Armaly Jr., president of Armaly Brands. “As more consumers discovered the product’s distinctive shape which allowed them to clean those hard-to-get-to areas and experienced the advantages of the Estracell material the demand for the product really took off. We had reports from buyers telling us that customers were asking for the product which was really a key component in allowing us to secure additional distribution.”
Armaly also is the maker of cleaning products Brillo, Auto Show and Armaly ProPlus.
Price Chopper announces executive appointments
SCHENECTADY, N.Y. Jerel Golub has been appointed president and COO of Price Chopper Supermarkets, the Northeastern chain announced Friday.
Golub had served as EVP and COO since February 2008, previously serving as SVP sales and merchandising and VP marketing, as well as several other positions in merchandising and finance. In his new role, he will supervise administration, supply chain, real estate and construction, the company said. Joe Kelley will take Golub’s place as EVP, having served as VP sales and merchandising since February 2008.
David Golub was promoted to VP administration, having served as VP store operations since May 2006 and previously serving as regional VP, zone director, private-label category manager, produce and general merchandise specialist and store manager.
Other promotions include Russell Zwanka, to VP sales, merchandising and marketing, Mike Davidson, to VP operations, Mark Chandler, to VP supply chain, and Bob Doyle, to VP distribution.
Decision Resources projects Vidaza will remain clinical gold standard through 2013
WALTHAM, Mass. Market research firm Decision Resources said Monday that a drug made by Celgene would remain its clinical gold standard for the next three years for underproduction of blood cells that often is a precursor to leukemia.
Celgene’s Vidaza (azacitidine) will remain the clinical gold standard through 2013 for myelodysplastic disorders, the firm said in its report, Myelodysplastic Syndromes (High-Risk): Azacitidine’s Position as Market Leader Will Not Be Usurped. However, Eisai’s Dacogen (decitabine) comes close to displacing Vidaza, though Decision Resources said its lack of strong survival data and other factors would prevent it from doing so.
“Celgene’s Vidaza is the only drug for high-risk myelodysplastic syndromes that offers a confirmed benefit in overall survival and the first hypomethylating agent to reach the U.S. and European markets,” Decision Resources analyst Andrew Merron said. “Despite this efficacy achievement, surveyed hematologists indicate that there is still considerable unmet need in improving patient survival.”